PTX signs next-gen anti-cancer platform from Penn & Oxford
Filed with ASX · · 6 pages · English
Prescient Therapeutics Limited on 6ix
In the deck
Earlier from Prescient Therapeutics
- Voluntary Suspension
- Pause in Trading
- PTX-100 progresses to new dose, adds new site
- March 2020 Quarterly Update and Appendix 4C
- December 2019 Appendix 4C - Quarterly
Later from Prescient Therapeutics
- Trading Pause
- 2 PTX Assets Chosen in Doherty Institute COVID-19 Program
- June 2020 Quarterly Update and Appendix 4C
- PTX-200 AML Trial Progresses to Next Dose Level
- PTX-100 progresses to next cohort in basket clinical study
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics